文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]FDG PET/CT 在鼻咽癌复发诊断与挽救治疗中的获益

Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-27

该研究比较 PET/CT、MRI 与超声在鼻咽癌复发检测中的效能,并评估其在分期、勾画和总生存中的获益。结果显示 PET/CT 检测局部复发的灵敏度高于 MRI(93.9% vs. 79.3%,P < 0.001),诊断淋巴结的灵敏度高于 MRI(90.9% vs. 67.6%,P < 0.001)且与超声相似。PET/CT 联合 MRI 分期者 3 年总生存高于单用 MRI 者(85.5% vs. 60.4%,P = 0.006;校正 HR = 0.34,P = 0.005)。

要点

  • PET/CT 检测局部复发灵敏度高于 MRI(93.9% vs. 79.3%,P < 0.001),特异性相似。
  • PET/CT 诊断淋巴结灵敏度高于 MRI(90.9% vs. 67.6%,P < 0.001),与超声相似。
  • PET/CT 联合 MRI 分期者 3 年 OS 高于单用 MRI 者(85.5% vs. 60.4%,P = 0.006)。

核心结论

  • PET/CT 能更准确地检测和分期鼻咽癌复发,并补充 MRI,在勾画和总生存方面提供获益。

研究设计与样本

  • 队列 A 纳入 1453 例有或无组织病理学确诊局部复发的患者,比较 PET/CT、MRI 与超声的灵敏度和特异性(McNemar 检验)。
  • 队列 B 纳入 316 例患者的 606 枚组织病理学确诊淋巴结,比较三种方法的灵敏度和特异性(McNemar 检验)。
  • 队列 C 为来自队列 A 的 273 例患者,队列 D 为来自队列 B 的 267 例患者,比较 PET/CT 与 MRI 的 rT 分期和 rN 分期分布及 rN 分期准确性(McNemar 检验)。
  • 队列 E 为从队列 A 随机抽取的 30 例患者,用相关样本 T 检验或 Wilcoxon 秩检验评估有无 PET/CT 时勾画的变化。
  • 队列 F 为 61 例经 PET/CT 联合 MRI 分期的 rT3-4N0M0 患者,队列 G 为 67 例经 MRI 分期的 rT3-4N0M0 患者,两组接受相似挽救治疗,用 log-rank 检验和 Cox 回归比较 OS。

主要发现

  • PET/CT 检测局部复发的特异性与 MRI 相似,但灵敏度高于 MRI(93.9% vs. 79.3%,P < 0.001)。
  • 诊断淋巴结时 PET/CT、MRI 与超声特异性相当,PET/CT 灵敏度高于 MRI(90.9% vs. 67.6%,P < 0.001),与超声相似。
  • 按 PET/CT 分期,更多患者为 rT3-4(82.8% vs. 68.1%,P < 0.001)或 rN+(89.9% vs. 69.3%,P < 0.001),rN 分期更准确(90.6% vs. 73.8%,P < 0.001)。
  • PET/CT 联合 MRI 辅助时局部复发勾画更精确(中位 Dice 相似系数 0.41 vs. 0.62,P < 0.001)。
  • PET/CT 联合 MRI 分期者 3 年 OS 高于单用 MRI 分期者(85.5% vs. 60.4%,P = 0.006;校正 HR = 0.34,P = 0.005)。

关键数值与推荐

  • 局部复发检测灵敏度:PET/CT 93.9% vs. MRI 79.3%(P < 0.001),特异性两者相似。
  • 淋巴结诊断灵敏度:PET/CT 90.9% vs. MRI 67.6%(P < 0.001),PET/CT 与超声相似,三者特异性相当。
  • rT3-4 比例:PET/CT 分期 82.8% vs. MRI 分期 68.1%(P < 0.001);rN+ 比例:89.9% vs. 69.3%(P < 0.001)。
  • rN 分期准确性:PET/CT 90.6% vs. MRI 73.8%(P < 0.001)。
  • 勾画精度中位 Dice 相似系数:PET/CT 联合 MRI 0.41 vs. 单用 MRI 0.62(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare PET/CT, MRI and ultrasonography in detecting recurrence of nasopharyngeal carcinoma and identify their benefit in staging, contouring and overall survival (OS). METHODS: Cohort A included 1453 patients with or without histopathology-confirmed local recurrence, while cohort B consisted of 316 patients with 606 histopathology-confirmed lymph nodes to compare the sensitivities and specificities of PET/CT, MRI and ultrasonography using McNemar test. Cohorts C and D consisted of 273 patients from cohort A and 267 patients from cohort B, respectively, to compare the distribution of PET/CT-based and MRI-based rT-stage and rN-stage and the accuracy of rN-stage using McNemar test. Cohort E included 30 random patients from cohort A to evaluate the changes in contouring with or without PET/CT by related-samples T test or Wilcoxon rank test. The OS of 61 rT3-4N0M0 patients staged by PET/CT plus MRI (cohort F) and 67 MRI-staged rT3-4N0M0 patients (cohort G) who underwent similar salvage treatment were compared by log-rank test and Cox regression. RESULTS: PET/CT had similar specificity to MRI but higher sensitivity (93.9% vs. 79.3%, P < 0.001) in detecting local recurrence. PET/CT, MRI and ultrasonography had comparable specificities, but PET/CT had greater sensitivity than MRI (90.9% vs. 67.6%, P < 0.001) and similar sensitivity to ultrasonography in diagnosing lymph nodes. According to PET/CT, more patients were staged rT3-4 (82.8% vs. 68.1%, P < 0.001) or rN + (89.9% vs. 69.3%, P < 0.001), and the rN-stage was more accurate (90.6% vs. 73.8%, P < 0.001). Accordingly, the contours of local recurrence were more precise (median Dice similarity coefficient 0.41 vs. 0.62, P < 0.001) when aided by PET/CT plus MRI. Patients staged by PET/CT plus MRI had a higher 3-year OS than patients staged by MRI alone (85.5% vs. 60.4%, P = 0.006; adjusted HR = 0.34, P = 0.005). CONCLUSION: PET/CT more accurately detected and staged recurrence of nasopharyngeal carcinoma and accordingly complemented MRI, providing benefit in contouring and OS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. OuYang PY, Liu ZQ, Lin QG, et al. Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 36301324. doi:10.1007/s00259-022-06020-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。